ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.
Merus Initiates a Phase 1 Clinical Trial of MCLA-158, a Bispecific Antibody Utilizing ADCC-enhancing GlymaxX® Technology